Lv21
160 积分 2024-05-02 加入
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
1小时前
待确认
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
2小时前
已完结
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases
1个月前
已完结
The therapeutic age of the neonatal Fc receptor
1个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
2个月前
已完结
Advantages of mesenchymal stem cell over the other stem cells
3个月前
已完结
Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
3个月前
已完结
皖公网安备34019202002308
